<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873910</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/009716</org_study_id>
    <nct_id>NCT02873910</nct_id>
  </id_info>
  <brief_title>Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Others</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Monocentric, Parallel-Group Study to Evaluate the Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Influence on Other Complaints and Its Tolerability: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the benefit and tolerability of IQP-AS-119 for
      reduction of susceptibility to infections and other complaints after extreme physical stress
      (participation in a marathon).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2016</start_date>
  <completion_date type="Actual">October 31, 2016</completion_date>
  <primary_completion_date type="Actual">October 31, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hooper's Index</measure>
    <time_frame>5 weeks</time_frame>
    <description>Compared between verum and placebo groups at baseline and all timepoints thereafter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress Questionnaire (PSQ20)</measure>
    <time_frame>5 weeks</time_frame>
    <description>Compared between verum and placebo groups at baseline and all timepoints thereafter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>URT symptoms recorded in daily dairy</measure>
    <time_frame>5 weeks</time_frame>
    <description>Compared between verum and placebo groups at baseline and all timepoints thereafter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily subject diary on URT symptoms and other health conditions (including Overall Treatment Effect (OTE)</measure>
    <time_frame>5 weeks</time_frame>
    <description>Compared between verum and placebo groups at baseline and all timepoints thereafter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wisconsin upper respiratory symptom survey (WURSS-21)</measure>
    <time_frame>5 weeks</time_frame>
    <description>Compared between verum and placebo groups at baseline and all timepoints thereafter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-12 (SF-12) Health Survey</measure>
    <time_frame>5 weeks</time_frame>
    <description>Compared between verum and placebo groups at baseline and all timepoints thereafter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of benefit (4-point categorical scale)</measure>
    <time_frame>5 weeks</time_frame>
    <description>Measured by the subjects/investigator at the final visit only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>5 weeks</time_frame>
    <description>Compared between verum and placebo groups at baseline and all timepoints thereafter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>5 weeks</time_frame>
    <description>Compared between verum and placebo groups at baseline and all timepoints thereafter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>5 weeks</time_frame>
    <description>Compared between verum and placebo groups at baseline and all timepoints thereafter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) throughout study</measure>
    <time_frame>5 weeks</time_frame>
    <description>Compared between verum and placebo groups at baseline and all timepoints thereafter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of tolerability (4-point categorical scale)</measure>
    <time_frame>5 weeks</time_frame>
    <description>Measured by the subjects/investigator</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Upper Respiratory Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>IQP-AS-119</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IQP-AS-119</intervention_name>
    <arm_group_label>IQP-AS-119</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Caucasian males and females, 18-65 years of age, residents of Berlin or Brandenburg

          2. Body mass index (BMI) 18.5-26.0 kg/m2

          3. Registered as runner for the 43rd BMW Berlin Marathon 2016

          4. History of at least 2 successful finished marathons (personal record of 3-5.5h within
             the last 5 years)

          5. History of post-exercise susceptibility to infections (e.g. upper respiratory tract
             symptoms) and/or other health conditions (infections, stress complaints) after
             strenuous exercise (eg. marathon, half-marathon, bicycle races, triathlons, heavy
             training loads) within the last 5 years (to be distinctly documented at screening)

          6. Readiness to comply with all study procedures, in particular:

               -  Consumption of the investigational product (IP) during the entire treatment
                  period of the study

               -  Maintaining the habitual diet, with the exception of consumption of maximal 2
                  garlic cloves per week

               -  Adapt pre-marathon training / physical activity to generally accepted proven or
                  individually successful training plan

               -  Adapt post-marathon training / physical activity to generally accepted proven or
                  individually successful recovery plan

               -  Filling in diaries and questionnaires

          7. Readiness to ensure generally proven or individually successful optimal food intake
             and rehydration before, during, and after the marathon.

          8. Non-smoker / smoking cessation of last ≥12 months prior to screening

          9. Regular sleeping pattern (no suspicion of sleep disorder) in the three months prior to
             screening

         10. Stable concomitant, permitted medication (if any) for at least last 2 weeks prior to
             screening and during the study

         11. Women of child-bearing potential only:

               1. negative pregnancy testing (Beta human chorionic gonadotropin (ß-HCG) in urine)
                  at screening

               2. commitment to use reliable contraception methods during the entire study

        Participation is based upon written informed consent form (ICF) by the participant
        following written and oral information by the investigator regarding nature, purpose,
        consequences and possible risks of the clinical study.

        Exclusion Criteria:

          1. Known sensitivity to any ingredients of the IP

          2. Additional strenuous exercise/activity other than regular occupational load,
             completing training runs / exercises prior the marathon. Additional strenuous
             exercise/activity other than regular occupational load and recovery exercise loads
             after the marathon

          3. History of severe cardiovascular disease or collapse during a running event (half
             marathon, marathon etc.) and/or training

          4. Hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90
             mmHg)

          5. Any abnormality observed in screening exercise ECG pointing to an increased
             cardiovascular risk (alternatively: any abnormality in the results of an exercise ECG
             performed in the last 6 weeks prior to screening pointing to an increased
             cardiovascular risk)

          6. Any chronic disease affecting the upper respiratory tract and the lungs, eg. asthma
             bronchial, chronic obstructive pulmonary disease, or ears-nose-throat (ENT) infection

          7. Acute infection of ENT or upper respiratory tract (URT) within the last month prior to
             screening

          8. Any nasal abnormalities:

               1. History of nasal reconstructive surgery

               2. Severe nasal septum deviation or other condition that could cause nasal
                  obstruction

               3. Presence of nasal ulcers or nasal polyps

          9. Active organ or systemic diseases including severe cardiovascular disease, diabetes
             mellitus, renal or liver disorder

         10. Known congenital or acquired immunodeficiency disease (e.g. HIV infection)

         11. Known bleeding disorders such as bleeding ulcers, or haemophilia

         12. Vaccination against influenza within 3 months prior to screening; any vaccination
             planned during the study

         13. Anticoagulants such as warfarin

         14. Systemic analgesics (other than paracetamol up to 2000mg/day or ibuprofen up to max.
             800 mg/day, or if medically indicated and prescribed by a physician), antibiotics
             (unless medically indicated and prescribed by a physician) or decongestant nose drops
             / spray (except for isotonic sea water, or if medically indicated and prescribed by a
             physician) during the study

         15. Use of medications or supplements influencing immune function (e.g. antihistamines,
             systemic corticosteroids, immune-suppressants), and physical performance, as per
             investigator's judgement, during the study

         16. Use of any doping substance as listed by the &quot;World Anti-Doping Agency&quot; at present or
             in the past, unless prescribed by a physician under a '&quot;therapeutic use exemption&quot;,
             per investigator's judgement

         17. Any use of food supplements containing vitamins, minerals, or trace elements, as per
             investigator's judgement, during the study

         18. Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals
             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)

         19. Women of child-bearing potential: pregnant or breastfeeding

         20. Participation in other studies within the last month prior to screening and during
             study

         21. Any other clinically significant condition which in the investigator's opinion could
             interfere with the results of the study or the safety of the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Uebelhack, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>analyze &amp; realize GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>analyze &amp; realize GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>January 1, 2018</last_update_submitted>
  <last_update_submitted_qc>January 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

